Patents Assigned to Bayer Aktiengesellschaft
-
Publication number: 20230151442Abstract: A lysis buffer comprising one non-ionic surfactant is provided which can be used as a one-step reagent of the preparation, storage, amplification, and/or detection of nucleic acids. Various embodiments of the lysis buffer of the invention comprise other substances that are compatible or useful in lysing cells, storing nucleic acids, amplifying nucleic acids, purifying nucleic acids, detecting nucleic acids, and/or other procedures for analysis of nucleic acids. Methods and kits based on the lysis buffer are also provided, including those for rapid lysis of cells and direct use of the resulting cell lysates in RT-PCR.Type: ApplicationFiled: April 1, 2021Publication date: May 18, 2023Applicant: Bayer AktiengesellschaftInventors: Stefan GOLZ, Holger SUMMER, Silke AIGNER, Heidrun ELLINGER-ZIEGELBAUER, Kirsten LEINEWEBER, Thomas MÜLLER
-
Patent number: 11647750Abstract: The present invention relates to novel active compound combinations comprising at least one known compound of the formula (I) and at least one further active compound, which combinations are highly suitable for controlling animal and microbial pests such as unwanted insects and/or unwanted acarida and/or unwanted nematodes.Type: GrantFiled: October 12, 2018Date of Patent: May 16, 2023Assignee: Bayer AktiengesellschaftInventors: Silvia Cerezo-Galvez, Christian Marienhagen, Holger Weckwert, Wolfgang Thielert, Marita John
-
Publication number: 20230148194Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: May 11, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Rienk OFFRINGA, Mareike GREES
-
Publication number: 20230139936Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: September 14, 2022Publication date: May 4, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Mareike GREES, Nicolas WERBECK, Benjamin BADER, Rienk OFFRINGA, Corinna LINK
-
Patent number: 11632958Abstract: Described is the use of compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram and a fungicide selected from the group of phosphonates, in particular fosetyl-aluminium for controlling Mosaic scab and reducing Venturia inequalis inoculum in apples, to a method for treating apple plants or apple plant parts for controlling Mosaic scab scab and reducing Venturia inequalis inoculum in apples and to a method for controlling Mosaic scab scab and reducing Venturia inequalis inoculum in plants and plant parts, in particular leaves by treating them with compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram and a fungicide selected from the group of phosphonates, in particular fosetyl-aluminium.Type: GrantFiled: December 17, 2018Date of Patent: April 25, 2023Assignee: Bayer AktiengesellschaftInventors: Sybille Lamprecht, Luk De Maeyer, Gilbert Labourdette
-
Publication number: 20230121195Abstract: The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 12, 2022Publication date: April 20, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Ilona GUTCHER, Ulrike RÖHN, Norbert SCHMEES, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Horst IRLBACHER, Michael PLATTEN
-
Publication number: 20230117034Abstract: The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 9, 2020Publication date: April 20, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BOEMER, Naomi BARAK, Philip LIENAU
-
Publication number: 20230115270Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.Type: ApplicationFiled: November 5, 2020Publication date: April 13, 2023Applicants: Bayer Aktiengesellschaft, Bayer AktiengesellschaftInventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Lisa DIETZ, Magdalena PLATZK, Daniel MEIBOM, Philipp BUCHGRABER, Niels LINDNER, Eva Maria BECKER-PELSTER, Carsten SCHMECK
-
Publication number: 20230113037Abstract: The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 10, 2020Publication date: April 13, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Julien LEFRANC, Norbert SCHMEES, Ludwig ZORN, Robin Michael MEIER, Simon Anthony HERBERT, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Mátyás GORJÁNÁCZ, Christina KOBER, Bernd BUCHMANN, Stephan BÖHME, Ulrich BOTHE, Michael PLATTEN, Daniel BAUMANN
-
Publication number: 20230112499Abstract: The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and poType: ApplicationFiled: December 14, 2020Publication date: April 13, 2023Applicant: Bayer AktiengesellschaftInventors: Olaf PANKNIN, Frank SACHER, Nicole SCHMIDT, Gernot LANGER, Katrin NOWAK-REPPEL, Reinhard NUBBEMEYER, Sabine PILARI, Antje ROTTMANN, Hideki MIYATAKE ONDOZABAL, Holger SIEBENEICHER, Antonius TER LAAK, Hana CERNECKA
-
Publication number: 20230106032Abstract: The present invention provides compounds of general formula (I): in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 5, 2021Publication date: April 6, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BÖMER, Naomi BARAK, Philip LIENAU
-
Publication number: 20230100584Abstract: The invention relates to the development of formulations, preferably for biologically active substances. The aim of the invention is to provide a method, a computer system, and a computer program product for predicting at least one property of at least one formulation using a prediction model which has been trained to predict formulation properties by means of a monitored learning process using reference data.Type: ApplicationFiled: February 18, 2021Publication date: March 30, 2023Applicant: Bayer AktiengesellschaftInventors: Holger DIEDAM, Johanna ANLAHR, Heike SKÖTSCH, Matthias ERBER
-
Patent number: 11613522Abstract: The invention relates to 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides of general formula (I) and to their agrochemically compatible salts (I) as well as to the use thereof in the field of plant protection.Type: GrantFiled: June 11, 2018Date of Patent: March 28, 2023Assignees: Bayer Aktiengesellschaft, Bayer CropScience AktiengesellschaftInventors: Olaf Peters, Klaus Bernhard Haaf, Guido Bojack, Katherine Rose Law, Anu Bheemaiah Machettira, Hansjoerg Dietrich, Elmar Gatzweiler, Christopher Hugh Rosinger, Elisabeth Asmus
-
COMBINATION OF AN AHR-INHIBITOR AND AN PD1-INHIBITOR ANTIBODY AND ITS USE IN THE TREATMENT OF CANCER
Publication number: 20230084899Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an AhR inhibitor, and component B being pembrolizumab or nivolumab. A further aspect of the present invention relates to combinations of three components, component A, component B, and component C; component A being an AhR inhibitor, component B being pembrolizumab or nivolumab, and component C being a further pharmaceutical agent. The present invention further relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment or prophylaxis of cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, kidney, head and neck, thyroid, parathyroid, and their distant metastases, lymphomas, sarcomas and leukemias.Type: ApplicationFiled: December 14, 2020Publication date: March 16, 2023Applicant: Bayer AktiengesellschaftInventor: Ilona GUTCHER -
Publication number: 20230072245Abstract: The present disclosure relates to substituted thiophene carboxamides derivatives, their use for controlling phytopathogenic microorganisms and compositions comprising thereof.Type: ApplicationFiled: December 17, 2020Publication date: March 9, 2023Applicant: Bayer AktiengesellschaftInventors: Jeremy DUFOUR, Thomas KNOBLOCH, Stephane BRUNET, Sybille LAMPRECHT
-
Publication number: 20230075876Abstract: The present invention relates to an enteric coated pharmaceutical composition comprising a solid dispersion comprising regorafenib and at least one stabilizing agent outside of the solid dispersion, its process of preparation and its use for treating disorders.Type: ApplicationFiled: February 1, 2021Publication date: March 9, 2023Applicant: Bayer AktiengesellschaftInventors: Martin Günter MÜLLER, Werner HOHEISEL
-
Publication number: 20230072421Abstract: A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 24, 2020Publication date: March 9, 2023Applicants: Bayer AS, Bayer AktiengesellschaftInventors: Niels BÖHNKE, Sabine ZITZMANN-KOLBE, Stefanie HAMMER, Sven WITTROCK, Donald BIERER, Thorsten POETHKO, Hans BRIEM, Holger Magnus STEUBER, Martina SCHÄFER, Robin Michael MEIER, Arif CELIK, Cornelia PREUSSE, Antje ROTTMANN, Nicolas WERBECK, Alexander KRISTIAN, Bård INDREVOLL, Alan CUTHBERTSON, Alex PAPPLE
-
Patent number: 11597901Abstract: Disclosed herein is a sterilizable adapter for a cell culture vessel comprising a body, an upper connection and/or a lid, at least one port, a ventilation passage, a lower internal connection suitable for connection to a cell culture vessel and a cell retention device and/or a cell separation device as well as a device comprising said sterilizable adapter and a method for cell cultivation using said sterilizable adapter.Type: GrantFiled: July 19, 2017Date of Patent: March 7, 2023Assignees: Bayer Aktiengesellschaft, BAYER HEALTHCARE LLCInventors: Annette Eidt, Wolf Kloeckner, Helmut Brod, Martin Poggel, Bernd Tscheschke
-
Patent number: 11597724Abstract: The invention relates to 3-phenylisoxazoline-5-carboxamides of tetrahydro- and dihydrofurancarboxylic acids and esters of the general formula (I) and their agrochemically acceptable salts and to their use in the crop protection sector.Type: GrantFiled: June 11, 2018Date of Patent: March 7, 2023Assignees: Bayer Aktiengesellschaft, Bayer CropScience AktiengesellschaftInventors: Olaf Peters, Klaus Bernhard Haaf, Stephen David Lindell, Guido Bojack, Katherine Rose Law, Anu Bheemaiah Machettira, Hansjoerg Dietrich, Elmar Gatzweiler, Christopher Hugh Rosinger
-
Patent number: 11599850Abstract: The invention relates to the monitoring of products by means of active radio tags. According to the invention, packagings of products are provided with an active radio tag that detects at least one environmental condition and/or at least one packaging state, and which emits a signal at time intervals, which provides information about a unique identifier and at least one state in which the respective product is found. The signal is picked up by a receiver that extracts the unique identifier and the state information and transmits same together with location information to an external server.Type: GrantFiled: January 18, 2019Date of Patent: March 7, 2023Assignee: BAYER AKTIENGESELLSCHAFTInventors: Christof Backhaus, Katharina Berger, Uwe Schenkel, Jürgen Schmidt, Walter Speth, Klaus Glismann, Eric Willms, Markus Storz, Arne Wendt, Gregory James Dibble